[go: up one dir, main page]

EP1844023A1 - Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité - Google Patents

Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Info

Publication number
EP1844023A1
EP1844023A1 EP05823851A EP05823851A EP1844023A1 EP 1844023 A1 EP1844023 A1 EP 1844023A1 EP 05823851 A EP05823851 A EP 05823851A EP 05823851 A EP05823851 A EP 05823851A EP 1844023 A1 EP1844023 A1 EP 1844023A1
Authority
EP
European Patent Office
Prior art keywords
amine compound
alkyl
compound
phenylquinazolino
ylquinazolino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05823851A
Other languages
German (de)
English (en)
Inventor
Nam Kyu Lee
Jun Won Lee
Sukho 404-904 Jugong Apt. LEE
Guang-Jin Im
Hye Young Han
Tae Kon Research Inst. of SK Chemicals Co Ltd KIM
Yong Hyuk Kim
Wie-Jong Kwak
Sang Woong Kim
Joohun 105-502 Gangchon Apt. HA
Eon Kyum 104-1101 Cheonggu Narae Apt. KIM
Jung Kyu Lee
Choong Yeul Yoo
Dae Yeon Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadgenex Inc
SK Chemicals Co Ltd
Kyung Hee University
Original Assignee
Leadgenex Inc
SK Chemicals Co Ltd
Kyung Hee University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadgenex Inc, SK Chemicals Co Ltd, Kyung Hee University filed Critical Leadgenex Inc
Publication of EP1844023A1 publication Critical patent/EP1844023A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and reducing body weight, and a preparation for treatment and/ or prevention of diabetes and/ or obesity, which comprises the compound as an active ingredient.
  • Diabetes one of the most common modern diseases, is on the increase in Korea, too. Because of its severe symptoms and sequela, the disease is becoming a social problem. Improvement of living standards and environments resulting form economic development has led to lack of exercises, while calorie intake has increased significantly. As a result, obesity and type 2 diabetes are also on the increase. If diabetes persists, blood lipid level increases, not to mention the blood glucose level, leading to cardiovascular diseases such as arteriosclerosis and coronary heart disease and complications such as diabetic kidney and retinal diseases. Therefore, development of a treatment for the above disease is an important issue.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • Insulin secretory defect refers to the condition in which the beta cells of the pancreas cannot secrete an adequate amount of insulin depending on the blood glucose level and includes both quantitative and functional secretory defects.
  • Insulin resistance refers to the condition in which target cells fail to respond to ordinary levels of circulating insulin. The cause of insulin resistance is generally thought of as hindered signal transfer after binding to the cell membrane receptor, resulting from genetic factors, obesity, reduced physical activity, hyperglycemia, abnormal blood lipid level, etc. What is important is that the two factors are related with each other. If there is insulin resistance, more insulin has to be secreted to overcome the resistance. And, hyperglycemia caused by insufficient secretion of insulin may aggravate the insulin resistance.
  • type 2 diabetes is related with obesity, but the exact mechanism of the interaction or interrelationship still needs to be elucidated.
  • the focus of the research on the cause of diabetes has recently shifted from "glucose metabolism” to "fatty acid metabolism.”
  • type 2 diabetes patients such lipid metabolism disturbances as increase in blood fatty acid level, increase in neutral fats, decrease in high-density lipoprotein cholesterol, accumulation of fats in muscles, increase in abdominal fats and fatty liver are frequently found, as well as hyperglycemia.
  • insulin resistance is thought to be the most important pathological cause of NIDDM. Insulin resistance is the condition in which glucose is not fully utilized even when there is a sufficient amount of insulin.
  • various hypoglycemic drugs are used to treat insulin resistance. The hypoglycemic drugs are classified as follows depending on the treatment mechanism and the target site:
  • Sulfonylurea based drugs promote the movement of insulin-containing granules in the beta cells of the pancreas, thereby promoting the secretion of insulin at second hand.
  • Sulfonylurea based drugs promote the movement of insulin-containing granules in the beta cells of the pancreas, thereby promoting the secretion of insulin at second hand.
  • Biguanide based drugs transfer glucose to muscle cells and inhibit gluconeogenesis in the liver. They are advantageous in that they do not cause hypoglycemia, but care should be taken for aged people and patients with cardiovascular diseases.
  • ⁇ -Glucosidase inhibitors inhibit the enzymatic action of glucose production in the small intestine, preventing abrupt increase of blood glucose level after meals. With few side effects, the drugs are used to treat mild cases of diabetes.
  • thiazolidione (TZD) based drugs are known to activate PPAR- ⁇ , which participates in the differentiation of fat cells.
  • these oral hypoglycemic drugs are not so effective in reducing blood glucose level and cause side effects, development of safer diabetic treatments is imminent.
  • search for new target proteins capable of regulating the signal transfer system and metabolism processes is essential for development of such treatment drugs.
  • AMPK 5'AMP-activated protein kinase
  • AMPK plays a variety of other roles in the body. Besides controlling insulin production in pancreatic cells, it inhibits activation of acetyl CoA carboxylase
  • ACC HMG-CoA reductase
  • AMPK plays a key role in energy homeostasis control and carbohydrate and lipid metabolism control, as activated by AMFs accumulated by muscle contraction, exercise or energy depletion in cells. Also, it is viewed as new target material for treating metabolic diseases, such as diabetes and obesity, caused by energy imbalance.
  • metabolic diseases such as diabetes and obesity
  • the importance of AMPK in glucose absorption during exercise is widely known.
  • the fact that the action of AMPK is independent of the insulin signal transfer system means that it can become a new target material for treatment of type 2 diabetics, most of whom show troubles with the insulin signal transfer system. Actually, a lot of type 2 diabetics could reduce their blood glucose level through exercise and the diabetic model animal test confirmed that exercise promotes activation of AMPK and decrease in blood glucose level.
  • metformin or thiazolidinedione (TZD) based drugs which are widely used as diabetic treatments at present, reduce blood sugar level partly by an AMPK-involved mechanism.
  • search of the drugs that can activate AMPK will lead to the development of a new-concept treatment that imitates the therapeutic effect of exercise on a variety of metabolic diseases.
  • the present inventors synthesized a novel material that has a remarkable effect in increase of AMPK activity and prevention and/ or treatment of obesity and diabetes and confirmed the effect.
  • the present inventors synthesized several compounds with quinazoline backbones and confirmed that they are superior in reducing blood glucose level and body weight.
  • a novel quinazoline compound effective in reducing blood sugar level and body weight, which is essential in treating diabetes and obesity.
  • a treatment for diabetes and obesity with no toxicity or side effects which comprises the novel quinazoline compound, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof as an active ingredient.
  • the present invention relates to a quinazoline derivative, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof effective in treating diabetes and obesity, which is represented by the formula 1 below:
  • R a is a substituent selected from hydrogen, (Ci-Ci8)alkyL (C 2 -Cs) alkenyl, (C2-C8)alkynyl, halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl, (Ci-C6)alkoxy-(Ci-C6)alkyl, cyano-(Ci-C 6 )alkyl, amino-(Ci-C 6 )alkyl, (Ci-C6)alkylamino-(C 1 -C6)alkyl, di-[(Ci-C6)alkyl]amino-(Ci-C6)alkyl, (Ci-C6)alkylthio-(Ci-C 6 )alkyl / (Ci-C 6 )alkylsulfinyl-(Ci-C6)alkyl and (Ci-C 6 )alkylsulfonyl-(Ci-C6)alkyl
  • N-(Ci-C 6 )alkylsulfamoyl N,N-di-[(Ci-C 6 )alkyl]sulfamoyl
  • X 3 is a direct bonding or selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S, N(R 7 )C(R 7 ) 2 ,
  • R 7 is a hydrogen atom, (Ci-C 6 )alkyl, aryl, aryl-(C 1 -C 6 )alkyl / (C 3 -C 7 )CyClOaIlCyI, (C3-C 7 )cycloalkyl-(C 1 -C 6 )alkyl /
  • any aryl, heteroaryl or heterocyclyl of R a may have 0 to 3 substituents, which may be identical or different and are selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxyl, carbamoyl, (Ci-C6)alkyl, (C2-Cs)alkenyl, (C2-C8)alkynyl, (Ci-C 6 )alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfiny
  • X 4 is a direct bonding or selected from O and N(R 9 ), wherein R 9 is a hydrogen atom or (Ci-C ⁇ )alkyl, and R 8 is selected from halogeno-(C 1 -C ⁇ )alkyl, hydroxy-(Ci-C6)alkyl
  • R b is a substituent selected from hydrogen, (C2-Cs)alkenyl, (C 2 -C 8 )alkynyl, halogeno-(d-C6)alkyl, hydroxy-(Ci-C 6 )alkyl,
  • (Ci-C 6 )alkylamino-(Ci-C 6 )alkyl di-[(Ci-C 6 )alkyl]amino-(Ci-C 6 )alkyl, (Ci-C 6 )alkylthio-(Ci-C 6 )alkyl, (Ci-C 6 )alkylsulfinyl-(Ci-C 6 )alkyl or
  • X 1 is a direct bonding or selected from O, S, SO, SO 2 , N(R 4 ), CO, CO 2 (R 4 ), CH(OR 4 ), CON(R 4 ), N(R 4 )CO, SO 2 N(R 4 ), N(R 4 )SO 2 , C(R 4 ) 2 O, C(R 4 ) 2 S, N(R 4 )C(R 4 ) 2 , N(R 4 )CON(R 4 ) and N(R 4 )CSN(R 4 ), wherein R 4 is a hydrogen atom, (Ci-QJalkyl, aryl, aryl-(Ci-C 6 )alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(Ci-C6)alkyl, (C3-C7)
  • X 3 is a direct bonding or selected from O, S, SO, SO 2 , N(R 7 ), CO, CH(OR 7 ), CON(R 7 ), N(R 7 )CO, SO 2 N(R 7 ), N(R 7 )SO 2 , C(R 7 ) 2 O, C(R 7 ) 2 S, N(R 7 )C(R 7 ) 2 , N(R 7 )CON(R 7 ) and N(R 7 )CSN(R 7 ), wherein R 7 is a hydrogen atom, (Ci-C 6 )alkyl,
  • X 4 is a direct bonding or selected from O and N(R 9 ), wherein R 9 is a hydrogen atom or (Ci-C6)alkyl, and R 8 is selected from halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl
  • CH 2 or HC ⁇ , selected from halogeno, carboxyl, carbamoyl, (Ci-C6)alkoxycarbonyl, N-(Ci-C6)alkylcarbamoyl, N,N-di-[(Ci-C6)alkyl]carbamoyl, amino-(Ci-C6)alkyl, (Ci-C 6 )alkylamino-(Ci-C6)alkyl and di-[(Ci-C 6 )alkyl]amino-(C 1 -C 6 )alkyl or -Q 5 -X 6 [wherein X 6 is a direct bonding or selected from CO and N(R 13 )CO, wherein R 13 is a hydrogen atom or (Ci-C 6 )alkyl, and Q 5 is aryl, aryl-(Ci-C6)alkyl, heteroaryl, heteroaryl-(C; ⁇ -C6)alkyl, heterocyclyl or heterocyclyl
  • any aryl, heteroaryl or heterocyclyl of R c may have 1, 2 or 3 identical or different substituents selected from hydrogen, halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxyl, carbamoyl, (Ci-C6)alkyl, (C 2 -Cs) alkenyl, (C2-C8)alkynyl, (Ci-C6)alkoxy, (C 2 -C ⁇ )alkenyloxy, (C 2 -C 6 ) alky nyloxy, (Ci-C 6 )alkylthio, (Ci-C6)alkylsulfinyl, (C 1 -C 6
  • N-(Ci-C6)alkyl-(C3-C 6 )alkynoylamino N-(Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C 1 -C 6 )alkanesulfonylamino and
  • X 8 is a direct bonding or selected from O and N(R 16 ), wherein R 16 is a hydrogen atom or (Ci-C 6 )alkyl
  • R 15 is selected from halogeno-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl, (Ci-C 6 )alkoxy-(Ci-C6)alkyl, cyano-(Ci-C 6 )alkyl, amino-(Ci-C6)alkyl, (Ci-C 6 )alkylamino-(C 1 -C 6 )alkyl and di-[(Ci-C 6 )alkyl]amino-(Ci-C 6 )alkyl or -X 9 -Q 7
  • X is a direct bonding or selected from O, S, SO, SO 2 and NR 5 , wherein R 5 is a hydrogen atom, (C 1 -C 6 )alkyl, aryl, aryl-(Ci-C6)alkyl, (C3-C7)cycloalkyl, (C 3 -C7)cycloalkyl-(Ci-C6)alkyl, heteroaryl, heteroaryl-(Ci-C6)alkyl, heterocyclyl or heterocyclyl-(Ci-C ⁇ )alkyl;
  • Ri is a substituent selected from hydrogen, (Ci-C8)alkyl, halogeno-(Ci-C 6 )alkyl, hydroxy-(d-C 6 )alkyl, (Ci-C 6 )alkoxy-(C 1 -C 6 )alkyl / amino-(Ci-C6)alkyl, (Ci-C6)alkylamino-(Ci-C 6 )alkyl, di-[(C 1 -C 6 )alkyl]amino-(C 1 -C 6 )alkyl and (Ci-C 6 )alkylsulfinyl or -X ⁇ -Q 1 [wherein X 1 is a direct bonding or selected from O, S and NR 5 and Q 1 and R 5 may be identical or different], the neighboring carbon atoms of (C2-C 6 )alkylene of Ri may be separated by a group selected from O, S and N(R 5 ), any CH 2 or CH3 of R 1 may
  • (C 1 -C6)alkoxycarbonyl, N-(d-C6)alkylcarbamoyl and N,N-di-[(C 1 -C6)alkyl]carbamoyl and heterocyclyl of R3 and R 4 may have 1 or 2 oxo or thioxo substituents.
  • X is O, S or NR 5 ;
  • R 1 is a hydrogen atom, C 1 -C 6 alkyl, C 1 -C 4 haloalkyl, C 1 -C 6 alkylhydroxy,
  • R 2 is Ci-Ci 8 alkyl, C 2 -C 8 haloalkyl, C 3 -C 7 cycloalkyl, (C 3 -C 7 )cycloalkyl
  • the compound represented by the formula 1 may form a pharmaceutically available salt, including an inorganic acid salt such as hydrochloride, sulfate, phosphate, bisphosphate, hydrobromate and nitrate or an organic acid salt such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • an inorganic acid salt such as hydrochloride, sulfate, phosphate, bisphosphate, hydrobromate and nitrate
  • an organic acid salt such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate and stearate.
  • Some of the compounds of the present invention may be crystallized or recrystallized using an aqueous or organic solvent. In that case, a solvate may be formed.
  • hydrates and other stoichiometric solvates belong to the scope of the present invention.
  • the compound represented by the formula 1 may be an enantiomer, a stereoisomer or a tautomer.
  • the isomers may be separated or decomposed by common methods or may be obtained by common stereospecific or asymmetrical synthesis methods.
  • the present invention also provides a preparation method of the quinazoline derivatives represented by the formula 1 and a pharmaceutically available salt thereof.
  • the present invention also provides a preparation method of the compound represented by the formula 1-1. As shown in the scheme 1 below, it may be synthesized from the subs titution reaction of a 4-chloro-2-substituted-quinazoline derivative represented by the formula 2 below and a compound represented by the formula 3 below: Scheme 1
  • the substitution reaction of the scheme 1 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compound represented by the formula 1-1 may be prepared from the substitution reaction of a 2-chloro-4-substituted-quinazoline derivative represented by the formula 4 below and a compound represented by the formula 5 below, as shown in the scheme 2 below:
  • the substitution reaction of the scheme 2 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compound represented by the formula 1-1 may be prepared from the substitution reaction of a 2-methyl-3H-quinazolino-4-one derivative represented by the formula 6 below, which is substituted by X at the number 4 position, and a compound represented by the formula 7 below, as shown in the scheme 3 below:
  • the substitution reaction of the scheme 3 is carried out in the presence of a base and an organic polar solvent.
  • a base an organic base such as pyridine or an alkylamine or an inorganic base such as an alkali metal salt or an alkaline earth metal salt may be used.
  • the compounds represented by the formulas 2 and 3 in the scheme 1, which are used as starting materials of the substitution reaction, may be prepared by the methods well known in the field of organic synthesis.
  • 2-ethylsulfanyl-3H-quinazolino-4-one is added thionyl chloride (SOCb) at -20 to 10 °C and reflux reaction is performed in the presence of an N,N-dimethylformamide catalyst in order to transform the ketone group at the C-4 position into chlorine (Cl).
  • SOCb thionyl chloride
  • R3 and R 4 are the same as defined in the formula 1.
  • an imidate compound is reacted with anthranilic acid and sodium methoxide (NaOMe) in the temperature range from room temperature to the reflux temperature of the solvent while stirring in order to prepare 3H-quinazolino-4-one with the substituent R 1 .
  • NaOMe sodium methoxide
  • phosphorus oxy chloride and diethylaniline are added and reaction is carried out in the temperature range from room temperature to the reflux temperature of the solvent while stirring to transform the ketone group at the C-4 position into chlorine (Cl).
  • R 1 is a hydrogen atom
  • alkyl or aryl may also be prepared by the scheme 6 below:
  • R 1 , R3 and R 4 are the same as defined in the formula 1.
  • an acyl halide is reacted with anthranyl amide and reflux reaction is carried out in the presence of NaOH to prepare 3H-quinazolino-4-one with the substituent R 1 .
  • phosphorus oxy chloride and diethylaniline are added and reaction is performed in the temperature range from room temperature to the reflux temperature of the solvent while stirring in order to transform the ketone group at the C-4 position into chlorine (Cl).
  • the compounds represented by the formulas 4 and 5 in the scheme 2, which are used as starting materials of the substitution reaction, may be prepared by the methods well known in the field of organic synthesis.
  • the compound represented by the formula 4 may be prepared by the scheme 7 below:
  • R 2 , R3, R4 and X are the same as defined in the formula 1.
  • the compound represented by the formula 3 may be used in excess as both organic solvent and reactant or another solvent may be used and the compound may be used stoichiometrically. And the reaction may be carried out in the presence of a base, if deemed necessary.
  • a base an organic base such as pyridine and an alkylamine or an inorganic base such as an alkali metal salt and an alkaline earth metal salt may be used.
  • the prepared intermediate compound and the target compound may be separated and purified by such common methods as chromatography and recrystallization.
  • the compounds of the present invention may be administered by an adequate administration method, for example, orally, intraorally, sublingually, rectally, vaginally, intranasally, locationally or non-orally (including intravenously, intracavernously, intramuscularly, subcutaneously and intraluminally).
  • an adequate administration method for example, orally, intraorally, sublingually, rectally, vaginally, intranasally, locationally or non-orally (including intravenously, intracavernously, intramuscularly, subcutaneously and intraluminally).
  • the general dosage of the compound represented by the formula 1 for treatment or prevention of diabetes and obesity is 0.1 to 400 mg/day for an adult weighing 70 kg.
  • the compound can be prepared into a tablet or capsule, using a pharmaceutically available excipient or vehicle, with the content of the compound of 0.05 to 200 mg, and administered once or several times a day.
  • the compound is administered in an amount of 0.01 to 100 mg.
  • the adequate dosage is determined by the doctor, considering the patient's age, body weight and other characteristics.
  • the aforementioned dosages are for general cases.
  • the dosage may be higher or lower from a patient to another.
  • the compound represented by the formula 1 may be administered alone or along with a pharmaceutical vehicle that is selected in consideration of the administration and other standard pharmaceutical practices.
  • the compound may be administered orally, intraorally or sublingually in the form of a tablet containing starch or lactose, ovules by itself or along with excipients or elixir or emulsion containing chemicals that offer specific flavors or colors.
  • the liquid preparation may be prepared by adding a pharmaceutically available additive such as a suspension (e.g., a mixture of semisynthetic glyceride like methylcellulose and witepsol or apricot kernel oil with PEG-6 ester or a glyceride mixture of PEG-8 and caprylic/capric glyceride). It may be administered non-orally, for example, intravenously, intracavernously, intramuscularly, subcutaneously or intraluminally. For non-oral administration, it is most preferable to use the compound in the form of sterile aqueous solution.
  • the solution may comprise other substances (for example, salts or monosaccharides such as mannitol and glucose) for isotonicity with blood.
  • the present invention provides a pharmaceutical composition comprising the compound represented by the formula 1 or a pharmaceutically available salt thereof, as an active ingredient, and a pharmaceutically available diluent or excipient.
  • the present invention also provides a pharmaceutical composition for medical use comprising the compound represented by the formula 1, a pharmaceutically available salt thereof or a pharmaceutically available prodrug thereof as an active ingredient.
  • FIG. 1 shows the result of Western blot analysis showing the degree of phosphorylation of the serine-79 for the compound of the present invention.
  • FIGs. 2a to 2g show the results of Western blot analysis showing the degree of phosphorylation of the serine-79 and threonine-172 for the compound of the present invention.
  • FIGs. 3a and 3b are graphs showing the change of blood glucose level when the compound of the present invention was abdominally administered to db/db mice.
  • FIGs. 4a and FIG. 4b are graphs showing the change of body weight when the compound of the present invention was abdominally administered to db/db mice.
  • FIGs. 5a, 5b and 5c are graphs showing the change of blood glucose level when the compound of the present invention was orally administered to db/db mice.
  • FIGs. 6a, 6b and 6c are graphs showing the change of body weight when the compound of the present invention was orally administered to db/db mice.
  • FIGs. 7a and 7b are graphs showing the change of body weight when the compound of the present invention was abdominally administered to ob/ob mice.
  • FIGs. 8a and 8b are graphs showing the change of blood glucose level when the compound of the present invention was abdominally administered to ob/ob mice.
  • FIG. 9 is a graph showing the change of body weight when the compound of the present invention was orally administered to ob/ob mice.
  • Example 4 Preparation of 4-substituted amine-2-phenylquinazoline (formula Ib) 4-Chloro-2-phenylquinazoline (formula 2b; 0.5 g, 2.08 mmol) was dissolved in 30 mL of THF. TEA (5 eq, 1.45 mL, 10.38 mmol) and amine (1.5 eq) were added and the mixture was stirred at room temperature overnight. When the starting materials disappeared, THF was removed by distillation under reduced pressure and the target compound was obtained with a yield of 90 % by column chromatography (silica gel; 230-400 mesh).
  • Example 9 Preparation of 2-substituted-3H-quinazolino-4-one (formula E) 2-(Substituted-carbonyl-amino)-benzamide (formula H; 45 mmol) was dissolved in 60 mL of 2.5N-NaOH and the mixture was refluxed for 1 hour. When the starting materials disappeared, the mixture was cooled to 0 "C and neutralized with 3N-HC1. The formed crystal was filtered and dried to obtain the target compound with a yield of 95 % (43 mmol).
  • the mixture was stirred at room temperature for 3 hours and ethanol was removed by distillation under reduced pressure when the starting materials disappeared.
  • the compound represented by the formula 1 may be prepared into a variety of preparation forms depending on the purpose. The following are non-limiting examples of some preparation forms comprising the compound represented by the formula 1 as an active ingredient.
  • a tablet for oral administration was prepared by wet granulation and dry granulation.
  • composition Active ingredient 200 mg, hard silicic anhydride 10 mg, magnesium stearate
  • composition Active ingredient 100 mg, mannitol 180 mg, dibasic sodium phosphate 25 mg, water for injection 2974 mg.
  • Experimental Example 1 Analysis of glucose absorption
  • C2C12 muscle cells were cultured in DMEM (Dulbecco's modified Eagle's medium) containing 10 % bovine calf serum. When the cell density increased to about 85 to 90 %, the culture medium was replaced with 1 % bovine calf serum and cell differentiation was induced for 6 days. Completely differentiated cells were cultured for 3 hours with Krebs-Ringer buffer (KRB) containing 5 mM glucose. The test materials were added at a concentration of 10 ⁇ M. 30 minutes later, 0.2 ⁇ Ci 2-deoxyglucose was added. KRB was removed 20 minutes later and the cells were washed for 3 times with cold PBS. The cells were lysed with 0.5N NaOH and counted using a radioactive counter.
  • KRB Krebs-Ringer buffer
  • C2C12 cells were cultured and differentiated in the same manner as in Experimental Example 1. Treatment with the test materials was also performed in the same manner as in Experimental Example 1 (10 ⁇ M for 50 minutes). The culture medium was removed and the cells were washed for 2 times with PBS and protein extracts were obtained using a lysis buffer (50 mM tris-HCl, pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM sodium o-vanadate, 1 mM NaF, 1 ⁇ g/ mL apronitin, 1 ⁇ g/mL leu-peptin, 1 ⁇ g/mL pepstatin). The AMPK activity was determined from Western blot analysis of the degree of phosphorylation of serine-79 by acetyl CoA carboxylase and the degree of phosphorylation of threonine-172. The amount of ERK
  • CMC carboxylmethylcellulose
  • CMC rosiglitazone dissolved in 0.5 % carboxylmethylcellulose
  • test material were administered orally or abdominally every afternoon to the negative control group, the positive control group and the test group, respectively.
  • Blood glucose level measurement was made just before the administration, at an interval of 3-4 days, by incising the tail vein. Body weight and the amount of feed were measured every day just before the administration.
  • test group to which the compound represented by the formula 1 had been administered abdominally or orally showed significant decrease in blood glucose level and body weight compared with the control group, which implies the preventive and therapeutic effect for diabetes and obesity.
  • mice 6- week old male ob/ob mice (Harlan) were accustomed to the environment of the animal breeding facility of SK for a week. During the period, the mice were freely given feed and water. The mice were grouped based on the body weight. The mice were grouped into the control group, the positive control group (sibutramine) and the test group. The administration dosage was 15 mg/kg for the positive control group and 200 mg/kg/10 mL for the test group. Administration was given abdominally using an insulin syringe. Administration was given once a day at 5 p.m. over a 4-week period. The control group was administered with 0.5 % carboxymethyl cellulose (CMC), at kg/ 1O mL.
  • CMC carboxymethyl cellulose
  • Body weight was measured over the 4-week period. The difference in the body weight of the control group and the body weight of the test group (g) and the increase of the body weight (%) were calculated to evaluate the inhibitive effect against body weight increase. Also, the amount of feed intake was measured in order to evaluate the inhibitive effect against feed intake.
  • Oral administration test was performed for the materials that showed effectiveness in Experimental Example 1. Grouping of the mice, administration dosage, administration period, etc. were the same as in Experimental Example 3-1. Forced oral administration was performed using a bouige.
  • FIGs. 8a and 8b and FIG. 9 the test group to which the compound represented by the formula 1 had been administered abdominally or orally showed significant decrease in blood glucose level and body weight compared with the control group, which implies the preventive and therapeutic effect for diabetes and obesity.
  • the compounds of the present invention are effective in lowering blood glucose level and body weight and can be used for treatment of diabetes and/ or obesity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de quinazoline qui permettent de diminuer le taux sanguin de glucose ainsi que la masse corporelle. La présente invention concerne également un médicament pour le traitement prophylactique et/ou thérapeutique du diabète et/ou de l'obésité, et qui comprend lesdits composés au titre de principes actifs.
EP05823851A 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité Withdrawn EP1844023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040117708 2004-12-31
PCT/KR2005/004664 WO2006071095A1 (fr) 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Publications (1)

Publication Number Publication Date
EP1844023A1 true EP1844023A1 (fr) 2007-10-17

Family

ID=36615173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05823851A Withdrawn EP1844023A1 (fr) 2004-12-31 2005-12-30 Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Country Status (4)

Country Link
EP (1) EP1844023A1 (fr)
JP (1) JP2008526734A (fr)
KR (1) KR20060079121A (fr)
WO (1) WO2006071095A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584485C (fr) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes et chalcones utilises pour la prevention et le traitement de maladies cardio-vasculaires
JP4966958B2 (ja) 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
FR2891829A1 (fr) * 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
WO2007071632A2 (fr) * 2005-12-20 2007-06-28 Neurosearch A/S Derives de pyridinyl-quinazoline et leur utilisation medicale
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
WO2008157500A1 (fr) * 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
WO2009000085A1 (fr) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Dérivés de quinoline et de quinazoline utiles comme modulateurs des canaux ioniques
BRPI0816881A2 (pt) 2007-09-21 2015-03-17 Array Biopharma Inc Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
EP2231666B1 (fr) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine servant a traiter les troubles métaboliques
EP2269993B1 (fr) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
NZ590913A (en) * 2008-07-11 2012-09-28 Myrexis Inc (2-aminomethylquinazolin-4-yl)-(4-methoxyphenyl)methylamine for treating or ameliorating neoplasm or cancer
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
PE20121153A1 (es) 2009-09-03 2012-08-27 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales ionicos de potasio
KR101467996B1 (ko) * 2010-04-30 2014-12-11 전북대학교산학협력단 에이디피-리보실 사이클라제 활성을 저해하는 퀴나졸린 유도체
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
CA2857302C (fr) 2011-12-15 2020-08-25 Novartis Ag Utilisation d'inhibiteurs de l'activite ou de la fonction de pi3k
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用
KR102205202B1 (ko) 2013-02-01 2021-01-21 웰스태트 테러퓨틱스 코포레이션 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
WO2016090299A1 (fr) * 2014-12-05 2016-06-09 Subramaniam Ananthan Nouvelles quinazolines en tant que modulateurs du transport d'amines biogènes
US9873702B2 (en) 2014-12-05 2018-01-23 Southern Research Institute Heterocyclic compounds as biogenic amine transport modulators
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN106045924B (zh) * 2016-07-28 2018-08-14 黑龙江八一农垦大学 一种芳基取代喹唑啉胺衍生物的合成方法
IL280213B2 (en) 2018-07-26 2024-06-01 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CA3178994A1 (fr) 2020-05-19 2021-11-25 Iyassu Sebhat Activateurs d'ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
TW202233195A (zh) * 2020-10-30 2022-09-01 加拿大商瑞斯弗洛吉克斯公司 以BET溴結構域抑制劑及鈉依賴型葡萄糖轉運2抑制劑之組合於降低HbA1c含量之方法
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN112608302B (zh) * 2020-12-28 2022-05-24 郑州大学第一附属医院 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
CN114315802B (zh) * 2021-12-14 2023-06-16 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途
WO2024136338A1 (fr) * 2022-12-22 2024-06-27 연세대학교 산학협력단 Composition comprenant un composé n-benzylquinazoline-4-amine pour prévenir ou traiter l'obésité ou des troubles métaboliques associés aux lipides
WO2025129135A2 (fr) * 2023-12-15 2025-06-19 Eikon Therapeutics, Inc. Compositions comprenant des inhibiteurs d'usp1 et leurs méthodes d'utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
KR20010089171A (ko) * 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2002062767A1 (fr) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
DE10224462A1 (de) * 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
WO2004087680A1 (fr) * 2003-03-31 2004-10-14 Taisho Pharmaceutical Co., Ltd. Nouveaux derives de quinazoline et leur utilisation therapeutique
CA2520323C (fr) * 2003-04-09 2013-07-09 Exelixis, Inc. Modulateurs de tie-2 et procedes d'utilisation
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006071095A1 *

Also Published As

Publication number Publication date
JP2008526734A (ja) 2008-07-24
WO2006071095A1 (fr) 2006-07-06
KR20060079121A (ko) 2006-07-05

Similar Documents

Publication Publication Date Title
WO2006071095A1 (fr) Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
US20080207614A1 (en) Quinazoline derivatives for the treatment and prevention of diabetes and obesity
CN102548983A (zh) 作为单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺
CN101531638B (zh) 用作雌激素相关受体调节剂的化合物及其应用
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
CA2437409C (fr) Azoles en inhibiteurs de la decarboxylase des malonyl-coa, convenant comme modulateurs metaboliques
DE602004009582T2 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
MXPA06007715A (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad.
BG63487B1 (bg) Използване на хетероциклени съединения
EA024703B1 (ru) Комбинация оланзапина и агониста taar1
TWI771303B (zh) 化合物及其於降低尿酸位準之用途(一)
US20050004103A1 (en) 4,4-Difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
TW201313708A (zh) 用於治療代謝性疾病與相關病症之單醯基甘油脂酶抑制劑
US20050176741A1 (en) Quinazoline derivative and medicine
CN114014796A (zh) 一类依巴斯汀的盐及其制备方法和应用
KR20030085005A (ko) 진양제
CN101827595B (zh) 作为神经肽y2受体调节剂的取代的哌嗪和哌啶类
KR20110092517A (ko) 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
US20090176780A1 (en) Nitrogenous heterocyclic compounds
KR100807515B1 (ko) 신규 화합물
KR101676889B1 (ko) 페닐이미다졸 화합물
KR101123071B1 (ko) 신규 이미다졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종의 예방 및 치료용 약학적 조성물
JP7390487B2 (ja) 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
EP3390355B1 (fr) Urées asymétriques de benzènesulfonyle et leurs utilisations médicales
US5116839A (en) Use of isoxazolin-3-one derivatives as antidepressants

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701